appConfigEntityId

bodyType

customContents

entityId

entityUuid

isVideo

articlePageQuery

article

articleSchemaContent

content

hooksArticlePageAdvertisementConfigArticle

hooksArticlePageFloatingButtonConfigArticle

appConfig

filter

json

liveArticle

Aileen Chuang

WuXi Biologics expects a sharp rise in full-year earnings for 2025, forecasting a 46.3 per cent increase in profit as it secures more projects across the drug development value chain, from discovery through to manufacturing.
In a positive profit alert filed with the Hong Kong stock exchange on Wednesday, the company said profit attributable to equity shareholders would reach about 4.91 billion yuan (US$710 million), while revenue is set to climb 16.7 per cent to 21.79 billion yuan.
Shares rose 3.4 per cent to HK$41.40 at close on Wednesday, extending their year-to-date gain to 31.7 per cent.
WuXi Biologics credited the performance to its “follow and win the molecule” strategy, which aims to secure work across the full life cycle of client drugs – from early research to late-stage development and commercial production – supported by its technology platforms and execution track record.
The model allows the group to partner with both emerging biotech firms and multinational drug makers, tracking client molecules through development while capturing late-stage and commercial manufacturing projects.
The company, headquartered in Wuxi, in Jiangsu province, eastern China, added 209 new integrated projects in 2025.
Among them were 23 under its “win the molecule” strategy, including six in Phase III trials and commercial production, bringing the total to 945, CEO Chris Chen said at the JPMorgan Healthcare Conference in San Francisco last month.
Chen said the company expected “sustainable high growth” in 2026, building on momentum in research, development and manufacturing.

WuXi Biologics said its 2025 results were supported by an expanded service offering, spanning early research, pre-investigational new drug work, clinical development and commercial manufacturing, with particularly strong demand in fast-growing segments such as bispecific antibodies and antibody-drug conjugates.
The company added that performance was also lifted by a broader range of services, stronger contributions from advanced technologies, improved utilisation of existing and newly built facilities, including its European plant, as well as cost savings, digitalisation and investment gains.
Jefferies analysts said the company’s growth momentum was likely to strengthen further this year, forecasting revenue to rise 21 per cent year on year in a January 15 report.
“Global expansion in the US, Singapore and Qatar helps mitigate geopolitical risks,” analysts led by Asia healthcare research head Cui Cui wrote.
The outlook comes against a backdrop of ongoing political scrutiny in Washington – including the risk of future inclusion on the US “Chinese Military Companies” list and other potential restrictions following the passage of the BioSecure Act – which could affect the company’s operations.


From US Fed rates to China’s global export share: 4 figures shaping markets

How Hong Kong’s new 5-year plan courts global capital with an eye on market dominance

Hong Kong stocks decline after Fed raises interest rates and signals more to come

US rate increase should only have short-term impact on Hong Kong stocks: CICC

Hong Kong stock market

WuXi Biologics earnings jump as  ‘follow and win the molecule’ strategy pays off

WuXi Biologics credits the performance to its “follow and win the molecule” strategy, which aims to secure work across the full lifecycle of client drugs. Photo: Shutterstock

The company, headquartered in Wuxi, in Jiangsu province, eastern China, added 209 new integrated projects in 2025. Photo: Handout

Chinese healthcare firms expand overseas to support growing expat community

Distinct Healthcare raised HK$284.53 million from its initial public offering in Hong Kong last week. Photo: Handout

A pharmacist processes the granules of traditional Chinese medicine at Gansu Provincial Hospital in Lanzhou, northwest China’s Gansu Province. Photo: Xinhua

Mainland China’s investors pour into Hong Kong-listed drug stocks, riding licensing wave

An employee works on a drug production line at a pharmaceutical company in Meishan, China, on January 30, 2024. Photo: NurPhoto via Getty Images

Shanghai Fosun Pharmaceutical’s pavilion at the China International Import Expo is seen on November 6, 2025. Photo: Daniel Ren

Fosun Pharma’s US$1.55 billion Eisai deal signals shift to long-term partnerships

A view of the Shanghai facility of Fosun Pharma’s biopharma unit Henlius. Photo: Handout

The Fosun Pharma pavilion at the China International Import Expo, November 6, 2026. Photo: Daniel Ren

Business

China Business

Markets

News

China Future Tech

Biomedicine

Chinese contract drug maker forecasts 46.3 per cent profit rise and signals continued growth despite US political scrutiny


Chinese contract drug maker forecasts 46.3 per cent profit rise and signals continued growth despite US political scrutiny.


WuXi Biologics earnings jump as ‘follow and win the molecule’ strategy pays off

.css-1c6uqr6{color:inherit;font-weight:inherit;font-size:inherit;font-family:inherit;line-height:inherit;overflow-wrap:break-word;}Chinese contract drug maker forecasts 46.3 per cent profit rise and signals continued growth despite US political scrutiny

Chinese contract drug maker forecasts 46.3 per cent profit rise and signals continued growth despite US political scrutiny